mtm laboratories and EMBL (European Molecular Biology Laboratory) in cancer link-up:
This article was originally published in Clinica
mtm laboratories (Heidelberg, Germany) is to validate the transcript, protein and tissue expression profiles of molecular marker candidates for colorectal and lung cancers under an agreement with the commercial arm of the European Molecular Biology Laboratory. It will fund the co-operative work through a Prolnno grant from the German ministry of economics, and will have commercialisation rights on identified markers. The two partners will make joint patent applications. The aim is to enable early detection and prevention of the cancers by combining EMBL's bioinformatics expertise and databanks with mtm's experience in marker-based diagnostics and therapeutics.
You may also be interested in...
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.